Artelo Biosciences, Inc. (NASDAQ:ARTL)
| Market Cap | 1.45M-91.5% |
| Revenue (ttm) | 0 |
| Net Income | -12.67M-20.6% |
| EPS | -74.28-81.0% |
| Shares Out | 387.28K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,726 |
| Open | 4.90 |
| Previous Close | 5.34 |
| Day's Range | 3.45 - 4.90 |
| 52-Week Range | 3.45 - 179.19 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 17, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ARTL
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
$ARTL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ARTL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ARTL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ARTL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ARTL Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Stock-based compensation | $971.00K | 47.30% |
| Professional fees | $866.00K | 42.18% |
| Employee and director compensation | $216.00K | 10.52% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ARTL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ARTL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ARTL
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $7.16K |
Estimated from each fund’s disclosed top holdings × AUM
ARTL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ARTL’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.